Published in Sci Rep on August 17, 2015
Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng (2016) 0.83
Composites of Polymer Hydrogels and Nanoparticulate Systems for Biomedical and Pharmaceutical Applications. Nanomaterials (Basel) (2015) 0.78
Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery. Ann Biomed Eng (2016) 0.75
A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation. J Mater Chem B Mater Biol Med (2015) 0.75
An introduction to biomaterial-based strategies for curbing autoimmunity. Exp Biol Med (Maywood) (2016) 0.75
Biomaterials Strategies for Generating Therapeutic Immune Responses. Adv Drug Deliv Rev (2017) 0.75
Dendritic cells in the host response to implanted materials. Semin Immunol (2017) 0.75
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 9.81
T cell anergy. Annu Rev Immunol (2001) 7.15
Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (2001) 6.14
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A (2000) 3.41
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Cytoplasmic DNA innate immune pathways. Immunol Rev (2011) 2.84
Designer self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional cultures. PLoS One (2006) 2.82
Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest (2005) 2.80
Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.75
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev (2009) 2.54
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 2.51
Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity (2010) 2.44
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol (1997) 2.10
Mechanism of action of clinically approved adjuvants. Curr Opin Immunol (2009) 2.06
CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol (1998) 2.04
Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol (1994) 2.03
Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00
Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc Natl Acad Sci U S A (2009) 1.98
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 1.94
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood (2002) 1.90
Functional differentiation of hepatocyte-like spheroid structures from putative liver progenitor cells in three-dimensional peptide scaffolds. Differentiation (2003) 1.70
Dynamic reassembly of peptide RADA16 nanofiber scaffold. Proc Natl Acad Sci U S A (2005) 1.68
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol (1997) 1.56
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Self-assembling short oligopeptides and the promotion of angiogenesis. Biomaterials (2005) 1.33
Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol (2000) 1.30
Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol (2000) 1.24
Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation (2006) 1.19
Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine (2008) 1.17
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev (2005) 1.15
The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev (2002) 1.12
Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol (2009) 1.11
Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun (2010) 1.10
Production of self-assembling biomaterials for tissue engineering. Trends Biotechnol (2009) 1.10
A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol (1997) 1.08
An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release (2011) 1.07
Adhesive substrate-modulation of adaptive immune responses. Biomaterials (2008) 1.05
In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials (2009) 1.05
Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia (2010) 1.05
Prevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes. Proc Natl Acad Sci U S A (2013) 1.03
Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol (2001) 1.02
Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J Immunol (2002) 1.02
Vaccines: from empirical development to rational design. PLoS Pathog (2012) 1.01
A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes (2008) 1.01
Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci U S A (2001) 1.00
Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials (2012) 0.99
The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. Biomaterials (2010) 0.99
Gradated assembly of multiple proteins into supramolecular nanomaterials. Nat Mater (2014) 0.99
Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J Biomed Mater Res A (2008) 0.99
A single-step immunization by sustained antigen release. J Immunol Methods (1979) 0.97
Contributions of surface topography and cytotoxicity to the macrophage response to zinc oxide nanorods. Biomaterials (2010) 0.96
Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC. Eur J Immunol (2008) 0.94
Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research. Curr Probl Pediatr Adolesc Health Care (2012) 0.93
IFN-gamma negatively regulates CpG-induced IL-10 in bone marrow-derived dendritic cells. J Immunol (2007) 0.92
CpG DNA: recognition by and activation of monocytes. Microbes Infect (2002) 0.92
Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood (2002) 0.91
A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines. Biomaterials (2009) 0.91
A self-adjuvanting supramolecular vaccine carrying a folded protein antigen. Adv Healthc Mater (2013) 0.90
Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells. Biomacromolecules (2005) 0.89
Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccin (2011) 0.89
Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives. J Control Release (2002) 0.88
Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum (2008) 0.88
Adhesive substrates modulate the activation and stimulatory capacity of non-obese diabetic mouse-derived dendritic cells. Acta Biomater (2010) 0.88
Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy (2005) 0.87
PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target (2008) 0.86
Modulation of leukocyte infiltration and phenotype in microporous tissue engineering scaffolds via vector induced IL-10 expression. Biomaterials (2013) 0.86
Intravital microscopy imaging of macrophage localization to immunogenic particles and co-localized tissue oxygen saturation. Acta Biomater (2010) 0.85
GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cell Immunol (2010) 0.85
Profiles of carbohydrate ligands associated with adsorbed proteins on self-assembled monolayers of defined chemistries. J Biomed Mater Res A (2010) 0.84
Integrin-directed modulation of macrophage responses to biomaterials. Biomaterials (2014) 0.83
IL-4/CCL22/CCR4 axis controls regulatory T-cell migration that suppresses inflammatory bone loss in murine experimental periodontitis. J Bone Miner Res (2015) 0.82
Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres. J Mater Chem B Mater Biol Med (2014) 0.82
Controlled release of insulin from self-assembling nanofiber hydrogel, PuraMatrix™: application for the subcutaneous injection in rats. Eur J Pharm Sci (2011) 0.81
Autoantigen based vaccines for type 1 diabetes. Discov Med (2011) 0.81
Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles. PLoS One (2013) 0.81
Clinical applications of colony-stimulating factors: a historical perspective. Am J Health Syst Pharm (2002) 0.78
TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. Ann Rheum Dis (2012) 0.78
The effect of cyclic mechanical strain on activation of dendritic cells cultured on adhesive substrates. Biomaterials (2013) 0.76